Policy Developments - The National Health Commission of China is taking measures to ensure blood supply in key areas and important time periods due to a noticeable decline in voluntary blood donations, influenced by factors such as aging population and lifestyle changes [2] - In 2024, the total blood supply in China is expected to decrease year-on-year, with a cumulative blood allocation of 3.613 million units, including 583,000 units allocated between provinces, representing a 35.1% increase [2] Drug and Medical Device Approvals - Kelun Pharmaceutical announced that its subsidiary has received drug registration approval for "Cefazolin Sodium/ Sodium Chloride Injection," which is packaged in a dual-chamber bag and is suitable for emergency treatment [4] - *ST Sailong's subsidiary has obtained a drug registration certificate for Famotidine Injection, classified as a Category A drug under the national medical insurance list, primarily used for treating upper gastrointestinal bleeding [5] Capital Market Activities - Borui Pharmaceutical plans to invest 20 million yuan to subscribe to the increased registered capital of Geek Gene Technology, acquiring a 4.1667% stake in the company [7] Industry Developments - Eli Lilly announced the launch of the multi-dose prefilled pen for Tirzepatide Injection in China, aimed at addressing the needs of the growing number of diabetes and obesity patients [9] - The adult overweight rate in China is 34.3%, with an obesity rate of 16.4%, highlighting the increasing demand for weight management treatments [9] - In the first quarter of this year, Tirzepatide contributed $6.15 billion in revenue to Eli Lilly, accounting for approximately 48% of the company's total revenue [10] - Hanyu Pharmaceutical has completed the enrollment of all subjects for the Phase III clinical trial of Semaglutide Injection for weight management, currently in the follow-up phase [11] Shareholder Actions - Nine Strong Bio's major shareholder completed a share reduction plan, reducing their holdings from 30,969,636 shares to 30,769,636 shares, a decrease from 5.30% to 5.26% of voting shares [13] - Yifeng Pharmacy's controlling shareholder plans to reduce their stake by up to 2%, amounting to no more than 24,248,336 shares [14]

Market Overview - Major U.S. index futures are down, with Dow futures falling by 0.55%, S&P 500 futures down by 0.41%, and Nasdaq futures decreasing by 0.38% [1] Chinese Stocks - Most Chinese stocks are experiencing declines, with Alibaba down over 2%, Li Auto down approximately 2%, JD.com down about 1%, Bilibili down around 1%, and Pinduoduo down nearly 1% [1] Boeing Incident - Boeing shares dropped over 7% following the news of a Boeing 787-8 Dreamliner crash in India, which was carrying 242 people [1] XPeng Motors - XPeng Motors saw a pre-market decline of 4.3% due to a breach of confidentiality by a media outlet that leaked product shooting content, which the company claims has caused significant operational disruption [1] Tencent Music - Tencent Music shares rose by 2.8% in pre-market trading, as Goldman Sachs highlighted the company's expansion into long-form audio and podcasting, proposing a potential acquisition aligned with its growth strategy, with a target price set at $15.5 [1] GameStop - GameStop's shares fell by over 10% in pre-market trading as the company announced plans to issue $1.75 billion in convertible bonds, which could be the largest convertible bond supply in the U.S. market for 2025 [2] Eli Lilly - Eli Lilly announced the launch of a multi-dose prefilled pen for Tirzepatide in China, aimed at increasing supply to meet patient demand, with each pen containing four fixed doses for weekly use [2] OpenAI Financing - OpenAI is reportedly in talks with Saudi and Indian investors to facilitate a $40 billion financing plan [2] Tesla FSD Approval - Elon Musk has called on the EU to expedite the approval process for Tesla's Full Self-Driving (FSD) technology, emphasizing the need for enhanced safety for Tesla vehicles in Europe [2]

Core Insights - Eli Lilly announced the launch of the multi-dose prefilled pen for Tirzepatide in China, following the successful introduction of Tirzepatide earlier this year [1] - The new injection device aims to increase supply in China and meet the demand of more patients [1] - Each pen contains four fixed doses, with one dose used per week [1]